[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639183":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":11,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":22,"collaborators":24,"id":28,"slug":11,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":11,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":11,"studyType":40,"phases":11,"briefSummary":41,"conditions":42,"keywords":11,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":11},{"fullName":5,"class":6},"Shanghai Mental Health Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change in the total score of the Hamilton Depression Rating Scale (HAMD-17) from baseline to follow-up.",null,"From enrollment to the end of treatment at 8 weeks",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","Patients from the outpatient or inpatient departments of Shanghai Mental Health Center",[18],{"type":19,"name":20,"description":21,"armGroupLabels":11,"otherNames":11},"DRUG","Therapeutic intervention","It does not interfere with specific clinical treatment decisions but observes patients under different treatment paths: ECT, Esketamine nasal spray, or conventional antidepressants.",{"type":23,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[25],{"name":26,"class":27},"Lingang National Laboratory","UNKNOWN","100639183",false,"NCT07602153","Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder","Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder - Sub-task 2: A Longitudinal Imaging-Proteomics Study on Suicidal Tendency and Mechanisms of Rapid Antidepressant Effects","Inclusion Criteria:\n\nAge 18-65; Han Chinese; meets DSM-5 criteria for MDD; suicidal ideation (HAMD-17 Item 3 score ≥ 2); education above primary school; provided written informed consent.\n\nExclusion Criteria:\n\nOther major mental disorders; unstable physical diseases (cardiovascular, hepatic, etc.); pregnancy or lactation; contraindications to Ketamine or ECT; history of drug or alcohol abuse within 6 months.","ALL","18 Years","65 Years",{"count":38,"type":39},130,"ESTIMATED","OBSERVATIONAL","This study focuses on the neurobiological changes in MDD patients with high suicidal risk during rapid antidepressant treatments, such as Esketamine and Electroconvulsive Therapy (ECT). Core ObjectivesEstablish a standardized longitudinal cohort for high-risk suicidal populations to ensure high-quality data for clinical transformation. Investigate the biological mechanisms of rapid-acting interventions by analyzing changes in brain function and molecular pathways. Develop predictive biomarkers to identify treatment responders early, thereby reducing ineffective trial-and-error treatments and lowering suicide risk. Methodology \\& Data CollectionThe study integrates multi-dimensional data across three critical time points: T0 (Baseline), T1 (Acute Phase\u002F24h post-first treatment), and T2 (Remission Phase\u002F4-6 weeks). Sample Cohort: A total of 130 participants (70 ECT, 30 Esketamine, 30 conventional medication). Multimodal Data Integration:Clinical Phenotyping: Standardized scales including HAMD-17 (Primary Indicator), C-SSRS (Suicide Assessment), and QIDS-SR16. Biological Omics: Whole Genome Sequencing (WGS), single-cell sequencing, proteomics, metabolomics, DNA methylomics, and gut metagenomics. Neuroimaging \\& Physiology: Functional MRI (fMRI), Diffusion Tensor Imaging (DTI), and 32-channel resting-state EEG. SignificanceBy capturing dynamic \"treatment-response\" trajectories, the project aims to move beyond descriptive symptoms to a system biology-based diagnosis. The findings are expected to provide scientific evidence for individualized intervention strategies and improve the efficiency of care for patients with treatment-resistant depression and acute suicidal ideation.",[43],"Major Depressive Disorder (MDD","NOT_YET_RECRUITING","2026-05-17",{"date":47,"type":48},"2026-05-22","ACTUAL",{"date":50,"type":39},"2026-05-30",{"date":52,"type":39},"2027-12-31",{"name":5,"class":6}]